Top Story

Genetic variant reduces coronary events, increases diabetes risk in familial hypercholesterolemia

June 30, 2015

CHICAGO — A PCSK9 loss-of-function genetic variant was associated with a cardioprotective effect, but increased prevalence of diabetes and prediabetes in patients with familial hypercholesterolemia, according to results presented at the National Lipid Association Scientific Sessions.

Researchers performed genotyping in 724 patients with familial hypercholesterolemia and established the presence of the PCSK9 InsLEU genetic variant to determine its potential link to diabetes, glucose homeostasis and coronary events.

In the Journals

Preventable risk factors related to half of CV deaths in US adults

June 30, 2015
Preventable risk factors accounted for half of CV deaths in U.S. adults aged 45 to 79 years from 2009 to 2010, according to an analysis published in the Annals of
VIDEO: Expert discusses relationship between statin therapy, diabetes Meeting News CoverageVideo

VIDEO: Expert discusses relationship between statin therapy, diabetes

June 12, 2015
CHICAGO — Health care professionals should be aware of the link between statin use and increased risk for type 2 diabetes, especially among patients with risk…
Rury Holman Meeting News CoveragePerspective

No additional threat of heart failure with Januvia in high-risk adults with type 2 diabetes

June 8, 2015
BOSTON – The DPP-IV inhibitor Januvia does not increase cardiovascular risk or benefit in adults with type 2 diabetes at high risk for acute cardiovascular events…
Cardiology Case Consults

The Patient with Acute Coronary Syndrome

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with acute coronary syndrome.
More »
Meeting News Coverage Video
VIDEO: Best CV disease treatment approach for patients with diabetes still unclear

VIDEO: Best CV disease treatment approach for patients with diabetes still unclear

May 31, 2015
SAN DIEGO — Spencer King, III, MD, MACC, of the cardiology department at Emory Saint Joseph’s Hospital and…
More »
Antiplatelet Therapy in ACS and PCI

Antiplatelet Therapy in ACS and PCI

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC.

It is estimated that in the United States, each year, over 780,000 persons will experience an acute coronary syndrome…
More »
Meeting News Coverage

Higher obesity increases odds for cardiovascular, cancer, diabetes deaths

July 8, 2014
Adults with class III obesity are more likely to die from all causes than those within normal weight range, but particularly from heart disease…
In the JournalsPerspective

'Bundled' management reduced diabetes-related vascular complications

July 3, 2014
A team-based model with an all-or-none or “bundled” approach to primary care reduced the risk for myocardial infarction, stroke and…
In the Journals

Sitagliptin may increase hospitalizations in patients with diabetes, HF

July 2, 2014
Recent study results found that sitagliptin use by patients with type 2 diabetes and HF may increase the risk for HF-related…
In the Journals

CV risk control differs by sex for patients with type 2 diabetes

July 2, 2014
Composite control of cardiovascular risk factors varies by sex for patients with type 2 diabetes, with women’s significantly lower than…
Meeting News Coverage

RYGB adds CV, quality-of-life benefits for obesity, type 2 diabetes

July 1, 2014
CHICAGO — Roux-en-Y gastric bypass surgery could bring additional benefits for some patients with obesity and type 2 diabetes, according to…
In the Journals

Homeless men boosted health playing pick-up soccer

June 29, 2014
As World Cup competition continues, a timely study published in the Scandinavian Journal of Medicine & Science in Sports showed that playing…
In the Journals

CABG, newer-generation DES yielded similar mortality rates in patients with diabetes

June 26, 2014
Comparable mortality rates were reported for patients with diabetes treated with CABG or PCI using a cobalt-chromium everolimus-eluting…
FDA News

FDA: No clear link between olmesartan, CV risk among patients with diabetes

June 24, 2014
The FDA today announced that a safety review of olmesartan indicates no increased risk for CV events among patients with diabetes.According to a…
Meeting News CoveragePerspective

Empagliflozin reduced BP for patients with type 2 diabetes, hypertension

June 23, 2014
CHICAGO — In patients with type 2 diabetes and hypertension, empagliflozin significantly reduced BP in addition to improving blood glucose…
Meeting News Coverage

More than 10% of patients with acute MI may have undiagnosed diabetes

June 16, 2014
It is estimated that about 10% of patients with MI may also have undiagnosed diabetes, according to new research presented at the American Heart…
More Headlines »